Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
Pedersen, Gabriel K.
Conserved epitopes are targets commonly researched to be part of universal vaccine candidates against influenza viruses (IV). These conserved epitopes need to be cross-protecting against distinct IV subtypes and to have a strong immunogenic potential. Nevertheless, subunit vaccines generally require a strong adjuvant to enhance their immunological effects. Herewith, we compare four different adjuvants differing in their immunological signatures that may enhance efficacy of a conserved hemagglutinin (HA)-epitope from IV, the NG-34, to define the most efficient combination of antigen/adjuvant to combat IV infections. Soluble NG-34 was mixed with adjuvants like aluminium hydroxide (AH) and AddaVax, known to induce Th2 and humoral responses; CAF01 which displays a biased Th1/Th17 profile and Diluvac Forte which augments the humoral response. Combinations were tested in different groups of mice which were subjected to immunological analyses. CAF01 + NG-34 induced a complete immune response with the highest IgG1, IgG2c titers and percentages of activated CD4 T cell promoting IFN-γ, IL-2 and TNF-α producing cells. Furthermore, in NG-34 stimulated mice splenocytes, cytokine levels of IFN-γ, IL-1β, IL-6, IL-10, IL-17 and TNF-α were also the highest in the CAF01 + NG-34 mouse group. This complete induced immune response covering the humoral and the cellular arms of the adaptive immunity promoted by CAF01 + NG-34 group suggests that CAF01 could be a good candidate as an adjuvant to combine with NG-34 for an efficacious vaccine against IV. However, more studies performed in IV hosts as well as studies with a challenge model are further required.
619 - Veterinària
Is part of
Sisteré-Oró, Marta, Gabriel K. Pedersen, Lorena Córdoba, Sergi López-Serrano, Dennis Christensen, and Ayub Darji. 2020. "Influenza NG-34 T Cell Conserved Epitope Adjuvanted With CAF01 As A Possible Influenza Vaccine Candidate". Veterinary Research 51 (1). doi:10.1186/s13567-020-00770-4.
Grant agreement number
EC/H2020/730964/ES/European Vaccine Research and Development Infrastructure/TRANSVAC2
MINECO/Programa estatal de I+D+I orientada a los retos de la sociedad/AGL2013-48923-C2-2-R/ES/Nuevas estrategias vacunales frente a enfermedades víricas ganaderas empleando pseudopartículas virales modificadas/
This item appears in the following Collection(s)
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/